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Abstract
Background: Debate continues about the optimal anticoagulation level for elderly Japanese patients with
non-valvular atrial fibrillation (NVAF) receiving warfarin. The Japanese Circulation Society guideline has recommended
prothrombin time-international normalized ratios (PT-INR) of 1.6 – 2.6 for elderly patients and 2.0 – 3.0 for non-elderly
patients, because previous observational studies indicated increased risk of bleeding when the ratio exceeded 2.6. We
aimed to reappraise the relationship between PT-INR and the risk of major bleeding in elderly Japanese patients.
Methods: From the electronic medical records, we selected a cohort of elderly (age≥ 70 years) Japanese patients with
NVAF who were prescribed warfarin for the prevention of thromboembolic diseases between November 2010 and
March 2014 at Kanto Rosai Hospital. We identified those who developed major bleeding (cases). For each case, we
randomly selected two matched controls by adopting a risk-set sampling method defined by calendar date, age,
gender, length of warfarin administration, and the prescriber of warfarin. The risk of major bleeding in patients having
PT-INR≤ 1.49, 1.50 – 1.99, 2.00 – 2.49 (the reference), 2.50 – 2.99, and≥ 3.00 were compared using the conditional
logistic regression method. The study protocol was approved by the IRB before the study was begun.
Results: Among the cohort of 806 elderly patients, we identified 32 cases and selected 64 matched controls. The
overall incidence of major bleeding was 3.5 per 100 patient-years. The odds ratios (95 % confidence intervals)
for the risk of developing major bleeding in patients with PT-INR≤ 1.49 (n = 20), 1.50 – 1.99 (n = 32), 2.00 – 2.49 (n = 18),
2.50 – 2.99 (n = 10), and≥ 3.00 (n = 16) were 1.0 (0.2, 5.9), 0.3 (0.1, 1.9), 1.0 (reference), 1.2 (0.2, 8.4), and 19.8 (2.0, 198.9),
respectively, with a significant difference between≥ 3.00 and reference.
Conclusions: Among elderly Japanese patients with NVAF, PT-INR 2.0 – 3.0 may be associated with a clinically
permissible risk of major bleeding while PT-INR≥ 3.00 a significant risk. Further studies are warranted to determine
whether the risk of major bleeding is significantly lower for PT-INR 2.50 – 2.99 than for PT-INR≥ 3.00.
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Background
Non-valvular atrial fibrillation (NVAF) is the most
prevalent arrhythmia in the elderly and poses substantial
morbidity and mortality risks because of an increase in
cardiogenic thromboembolic complications [1]. Oral
anticoagulant therapy has been shown to be effective in
reducing the risk of thromboembolic events in patients
of all age groups. While many non-vitamin K antagonist
oral anticoagulants (NOACs) have become available,
their use for elderly patients is still limited because of a
paucity of information regarding their safety profiles in
the elderly population [2–5]. As a result, warfarin is still
most frequently used in these patients. Nevertheless,
debate continues regarding the optimal intensity of war-
farin therapy in elderly Japanese patients with NVAF.
While the prothrombin time-international normalized
ratio (PT-INR) range of 2.0 – 3.0 is recommended for
Caucasians regardless of age and for non-elderly Japanese
patients, the range of 1.6 – 2.6 has been recommended for
elderly (age ≥ 70 years) Japanese patients [6–10].
One of the reasons for recommending a lower PT-INR
range (1.6 – 2.6) for elderly Japanese patients is that an ob-
servational study on approximately 200 Japanese NVAF
patients of all ages for the secondary prevention of stroke
demonstrated an increased risk of major bleeding for PT-
INR ≥ 2.60 [11]. Unfortunately, the study estimated the risk
of major bleeding for PT-INR ≥ 2.60 as a whole, and it re-
mains unclear if PT-INR 2.6 – 3.0 would be associated with
an increased risk compared to PT-INR 1.6 – 2.6. Recent
large cohort studies conducted in Japanese patients with
NVAF confirmed that PT-INR 2.0 – 3.0 should be consid-
ered the target range for non-elderly Japanese patients,
considering the balance between risk of bleeding and anti-
thrombotic efficacy [12]. However, there is a relative lack of
information regarding the bleeding risk at PT-INR 2.6 – 3.0
in elderly Japanese patients receiving warfarin [13, 14].
A case-control study design would complement pro-
spective randomized or cohort studies in assessing the
risk of outcomes with low event rates (such as major
bleeding caused by warfarin). Indeed, an optimal PT-
INR range of 2.0 – 3.0 for warfarin was first proposed
from case-control studies conducted by Hyleck et al.
[15, 16] in the early 1990s. With the availability of elec-
tronic medical record systems in community hospitals,
hospital pharmacists can now conduct case-control stud-
ies using real-world clinical data. In the present study, we
aimed to assess whether elderly Japanese patients with
PT-INR 2.5 – 3.0 have different risk of major bleeding
compared to those with PT-INR 2.0 – 2.5 or ≥ 3.0.
Methods
Retrieving case patients developing major bleeding
The present study was performed at the Japan Labour
Health and Welfare Organization Kanto Rosai Hospital
with 610 beds located in an urban area of Tokyo. Pa-
tients eligible for the present study were retrieved retro-
spectively from the electronic medical records between
November 2010 and March 2014, utilizing as indices
atrial fibrillation in the diagnosis [I48 by International
Statistical Classification of Diseases and Related Health
Problems, 10th revision (ICD-10)] and age (≥70 years).
We also extracted elderly (age ≥ 70 years) patients who
were prescribed warfarin using records of the electronic
prescribing system. Patient retrieved from both data-
bases were combined. Then those who were prescribed
warfarin for clinical indications other than prevention of
thromboembolic events associated with NVAF were
excluded to obtain the final cohort for the present case-
control study.
The electronic medical records were searched for oc-
currence of major bleeding events in the cohort using
the following ICD-10 codes as event identifiers: D69
(purpura and other hemorrhagic conditions), I60 to 62
(subarachnoid hemorrhage, intracerebral hemorrhage, and
other nontraumatic intracranial hemorrhage), K25.0, .2, .4,
and .6 (gastric ulcer: acute with hemorrhage or perfor-
ation, chronic with hemorrhage or perforation), K26.0, .2,
.4, and .6 (duodenal ulcer: acute with hemorrhage or per-
foration, chronic with hemorrhage or perforation), K27.0,
.2, .4, and .6 (peptic ulcer, site unspecified: acute with
hemorrhage or perforation, chronic with hemorrhage or
perforation), K28.0, .2, .4, and .6 (gastrojejunal ulcer: acute
with hemorrhage or perforation, chronic with hemorrhage
or perforation), K29.0 (acute hemorrhagic gastritis), K62.5
(hemorrhage of anus and rectum), K92.0, .1, and .2 (hema-
temesis, melena, gastrointestinal hemorrhage unspecified),
and R04 (hemorrhage from respiratory passages). Because
no consensus has been reached regarding the criteria for
major bleeding, we adopted the following composite cri-
teria by modifying that used in the RE-LY study [17]. Spe-
cifically, we considered the recorded bleeding events to be
compatible with major bleeding when at least one of the
following conditions was met: a reduction of blood
hemoglobin level of 2 g/dL or greater from the nearest
preceding value, a reduction of hemoglobin level below
8 g/dL, blood transfusion was undertaken, or bleeding
events were judged to necessitate hospitalization for trans-
fusion and other necessary therapies. Because the last
criterion is less objective and may be inconsistent between
attending physicians, we performed an additional analysis
by excluding the cases that were considered to develop
major bleeding solely based on the last criterion. Whether
the cases retrieved from the databases met the criteria of
major bleeding was determined by two authors independ-
ently: A.O. (pharmacist) and A.N. (physician). Data of PT-
INR associated with major bleeding episodes were
collected from the medical records when patients visited
the outpatient clinic or emergency department. In the case
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of emergency, the data immediately after admission were
collected.
Assignment of controls
For each case patient, we randomly assigned two control
patients by adopting a risk-set sampling method defined
by the calendar date of the bleeding event, age, gender,
length of warfarin administration, and the prescriber of
warfarin [18]. In control patients, data of PT-INR near-
est to the calendar date when their corresponding case
patients developed major bleeding were used.
Retrieving clinical data relevant to risk analysis
Age, gender, height, weight, estimated glomerular filtra-
tion rate (eGFR), PT-INR, warfarin doses, and other clin-
ical data required to calculate CHADS2 and HAS-BLED
scores were extracted from the medical records of the re-
trieved patients [19, 20]. For calculating the HAS-BLED
scores we searched for anti-platelet drugs and NSAIDs. In
addition, we searched for the concomitant medications
which might have inhibited the metabolic activity of
CYP2C9 or augmented the anticoagulation effects of
warfarin. They included acetaminophen, allopurinol, ami-
odarone, azole antifungal drugs, cimetidine, fluoroquino-
lones, macrolide antibiotics, metronidazole, propafenone,
SSRIs, statins, sulfa antibiotics. Labile PT-INR [percent
time within the therapeutic range in total therapeutic
period (TTR) < 60 %] was calculated using the Rosendaal
method [21]. The method assumes that changes between
consecutive PT-INR measurements are linear over time.
We calculated TTR assuming that PT-INR 1.6 – 2.6 is the
therapeutic range for elderly Japanese patients with NVAF
according to the 2013 guideline of the Japanese Circula-
tion Society [10]. We excluded the following periods from
calculation of TTR: within 7 days after the commence-
ment of warfarin therapy and periods when warfarin was
discontinued for any reason. We calculated TTR only
when the PT-INR data for more than 6 consecutive
months were available and when the longest measurement
intervals were less than 3 months apart.
Ethical issues
The present study was planned and conducted in compli-
ance with the Strengthening the Reporting of Observa-
tional Studies in Epidemiology (STROBE) statement and
the Declaration of Helsinki. The protocol was approved by
the institutional review board of Kanto Rosai Hospital
(the approval # 2014–14).
Statistical analysis
Comparisons of continuous variables were performed by
paired t-test and those for categorical variables by
McNemar’s test. We stratified the case and control pa-
tients into five categories according to their PT-INR values
(≤1.49, 1.50 – 1.99, 2.00 – 2.49, 2.50 – 2.99, and ≥ 3.00).
The risk of major bleeding for each group was evaluated
by conditional logistic regression analysis and expressed
as odd ratio (OR) and 95 % confidence interval (CI) versus
patients with PT-INR 2.00 – 2.49 (reference).
We performed power calculation for the statistical
analysis of a case-control study before we began the
study, according to the method reported previously [22].
We made the assumption that approximately 10 % of
control and 30 % of case patients had been exposed to
PT-INR ≥ 2.60. Based on this assumption and a case-
control matching ratio of 1:2, we estimated that at least
34 cases and 68 controls are required for detecting a sig-
nificant difference in the risk (OR) of developing major
bleeding with an α error of 5 % and a power of 80 %. In
addition, we performed power calculation for a cohort
study according to the method reported elsewhere [22].
We assumed that the event rates of major bleeding in
patients exposed to PT-INR ≥ 2.60 and < 2.60 were 15 %
and 3 % person-years, respectively, according to the data
reported in previous study [14] and that the size ratio
between the former and latter group was 1:9. A p
value less than 0.05 was considered statistically sig-
nificant throughout the study. The analysis was per-
formed using JMP Pro v.11 software (SAS Institute
Inc., Cary, NC, USA).
Results
Seven hundred and sixty-nine elderly patients who were
diagnosed with atrial fibrillation were extracted from the
electronic medical records. In addition, 1,048 elderly pa-
tients prescribed warfarin were extracted from the pre-
scription record database. Combining the two sets of
data and collating overlapping patients, we identified
1,122 elderly patients who had atrial fibrillation and/or
had received warfarin. Excluding 316 patients who were
prescribed warfarin for clinical indications other than
atrial fibrillation or who had valvular heart disease, the
final study cohort comprised 806 elderly Japanese pa-
tients with NVAF who received warfarin (Fig. 1). Among
a total of 918 person-years on warfarin therapy in the
cohort, we identified 32 major bleeding events (3.5 per
100 patient-years) including 16 gastrointestinal hemor-
rhages, 8 intracranial hemorrhages, 5 coagulation disor-
ders, and 3 respiratory tract hemorrhages. The number
of case patients largely met the estimated size by power
calculation. The demographic and clinical characteristics
of the case and control patients are listed in Table 1. No
significant differences in CHADS2 and HAS-BLED
scores were observed between the two groups. The
CHADS2 and HAS-BLED scores (both, 3 ± 1) were iden-
tical in the two groups. In addition, there was no signifi-
cant difference in the numbers of patients receiving
CYP2C9 inhibitors or those augment anticoagulation
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effect of warfarin: 17 of 32 (53 %) cases and 35 of 64
(55 %) controls ingested at least one of the above drugs
by McNemar’s test. The PT-INR (median; interquartile
range) for the cases (2.62; 1.97 – 5.30) was significantly
(p < 0.05) greater than the ratio for the controls (1.75;
1.52 – 2.14) (Fig. 2). While approximately 50 % of the
case patients showed PT-INR ≥ 2.60, only approximately
10 % of the control patients showed PT-INR ≥ 2.60 (OR
11.8; 95 % CI, 3.8 – 37.1). Collectively, these data largely
agree with the preconditions for power calculation.
When the risk of developing major bleeding in pa-
tients with different PT-INR ranges were compared
using the risk for PT-INR 2.00 – 2.49 as reference
(OR = 1), ORs for patients with PT-INRs 2.50 – 2.99,
1.50 – 1.99, and ≤ 1.49 were not significantly different
from the reference, whereas OR for patients with PT-
INR ≥ 3.00 was significantly (p < 0.05) greater than that
of the reference (Fig. 3).
In addition, the result of power calculation for a co-
hort study revealed that one-year follow-up of at least
400 patients (16 patients expected to develop major
bleeding) is required to obtain sufficient power for de-
tecting a significant difference in the risk of bleeding
between patients exposed to PT-INR ≥ 2.60 and those
exposed to < 2.60.
Five patients were considered to develop major bleed-
ing solely by the criterion of clinical judgement of the
necessity of admission. When the statistical analysis was
performed by excluding these data, essentially similar re-
sults were obtained (data are not shown).
Discussion
To the best of our knowledge, this is the first nested
case-control study carried out to assess the relationship
between PT-INR and the risk of developing major
hemorrhage in elderly Japanese patients with NVAF
receiving warfarin. Our data show that patients having
PT-INR ≥ 3.00 had approximately 20 times greater risk
of developing major bleeding compared to patients hav-
ing PT-INR 2.00 – 2.49 (reference), whereas those with
PT-INR 2.50 – 2.99 appeared to have similar risk (OR
1.23) compared to the reference. Our data support the
notion that the upper limit of target PT-INR for elderly
Japanese patients with NVAF may be extended to 3.00.
Target PT-INR of 2.0 – 3.0 has been recommended for
non-elderly Japanese patients. It is noteworthy that both
case and control patients participating in the present
study had a high risk of thromboembolic complications,
because the mean age of both groups was 81 years and
both had a median CHADS2 score of 3 [19]. In addition,
they had a high risk of bleeding during anticoagulation
therapy because of their ages and HAS-BLED scores
(Table 1). In this context, they represent elderly patients
in the real-world and therefore the results of the present
study would be relevant to daily medical practice.
Our data in general agree with previous studies. A
subgroup analysis of elderly (age ≥ 70 years) patients in the
J-Rhythm registry showed that the hazard ratio (95 % CI) of
major bleeding in patients with PT-INR 2.00 – 2.59, 2.60 –
2.99, and ≥ 3.00 increased gradually to 2.87 (1.12 – 7.35),
3.99 (1.33 – 11.89), and 7.02 (2.23 – 22.13), respectively,
Fig. 1 Flowchart of the retrieval, collation and integration of patient data
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against those who did not receive warfarin. Nevertheless,
the 95 % CIs of these groups overlapped substantially [12].
Naganuma et al. conducted a cohort study of 845 elderly
Japanese patients with NVAF and found that those with
PT-INR ≥ 3.00 had remarkably higher incidence of major
bleeding (20 per patient-year) compared to those with PT-
INR 2.00 – 2.49 (1.5 per patient-year) and 2.50 – 2.99 (3.4
per patient-year) [14]. However, the 95 % CI for PT-INR
2.50 – 2.99 (95 % CI, 0.9 – 8.5) overlapped substantially
with that for 2.00 – 2.49 (95 % CI, 0.6 – 3.2). Collectively,
we speculate that it would be practically impossible to
obtain statistically significant difference in major bleeding
risk between PT-INR 1.6 – 2.6 and 2.6 – 3.0. In contrast, it
may be possible to detect a significant difference in bleeding
risk between the target PT-INR (irrespective of 1.6 – 2.6 or
2.0 – 3.0) and PT-INR higher than 3.0. To achieve such
purpose, a case-control study design is useful, and was used
by Hylek et al. [15, 16] to establish the current target PT-
INR 2.0 – 3.0 for Caucasians. We calculated that the
present study comprising 96 patients had comparable
statistical power as a cohort study of 400 patients. Thus a
case-control study would be more practicable than a cohort
study to estimate the risk of drugs in a special population
such as the elderly.
The present study has several drawbacks. First, we were
unable to analyze the risk of intracranial hemorrhage at
different PT-INR levels separately, because only a
small number of events (n = 8) were observed in our
cohort. A recent study has reported that the risk of
intracranial hemorrhage in elderly Japanese may in-
crease approximately four-fold (OR 4.2; 95 % CI, 1.8 –
9.8) at PT-INR 2.5 – 3.0 [13]. Ultimately, the optimal
target PT-INR for elderly patients with NVAF should
be estimated in light of all-cause mortality as reported
by Oden and Fahlen [23]. They performed a medical
record linkage study in 42,451 Caucasian patients and
found that patients with PT-INR 2.0 – 2.4, 2.5 – 2.9,
and 3.0 – 3.4 had all-cause mortalities of 42.3, 47.4,
and 67.9 per 1,000 patient-years, respectively. At
present, no such data are available for the Japanese
population. Second, the present study has insufficient
numbers of cases for estimating OR with narrow 95 %
CI ranges in patients with the PT-INR ≥ 3.0, primarily
because the study was conducted in a single medical
center. Third, we did not examine the genetic polymor-
phisms of VKORC1 and CYP2C9 which are known to
influence on the inter-individual variability and risk of
bleeding in patients receiving warfarin. As a result, we
cannot make any inference on the contribution of these
Fig. 2 Distribution of prothrombin time-international normalized ratio
(PT-INR) in control and case patients. Median PT-INR (interquartile
range) for case and control patients are 2.62 (1.97 – 5.30) and
1.75 (1.52 – 2.14), respectively. A significant difference is detected
by paired t-test
Table 1 Clinical characteristics of case and control patients
Characteristics Cases (n = 32) Controls
(n = 64)
P value
Age (yr), mean ± SD 81 ± 5 81 ± 5 NS
Gender, M/F 14/18 28/36 NS
PT-INR
Median PT-INR(Q1,Q3) 2.62 (1.97, 5.30) 1.75 (1.52, 2.14) <0.05
≤1.49, n (%) 5 (16) 15 (24) NS
1.50 to 1.99, n (%) 3 (9) 29 (45) <0.05
2.00 to 2.49, n (%) 5 (16) 13 (20) NS
2.50 to 2.99, n (%) 4 (12) 6 (9) NS
≥3.00, n (%) 15 (47) 1 (2) <0.05
eGFR (mL/min/1.73 m2),
mean ± SD
43 ± 27 49 ± 15 NS
CHADS2 score, mean ± SD 3 ± 1 3 ± 1 NS
Congestive heart failure,
n (%)
19 (59) 19 (30) <0.05
Hypertension, n (%) 22 (69) 50 (78) NS
Diabetes, n (%) 5 (16) 21 (33) NS
Stroke/TIA, n (%) 16 (50) 23 (36) NS
HAS-BLED score, mean ± SD 3 ± 1 3 ± 1 NS
Impaired renal function, n (%) 7 (22) 3 (5) <0.05
Impaired liver function, n (%) 4 (13) 3 (5) NS
Stroke, n (%) 14 (44) 22 (34) NS
History of bleeding, n (%) 10 (31) 14 (22) NS
Labile PT-INR, n (%) 2 (6) 19 (30) NS
Antiplatelet or NSAID, n (%) 12 (38) 24 (38) NS
Alcohol consumption, n (%) 1 (3) 4 (6) NS
Q1 and 3 represent the upper limits of the first and third interquartile ranges.
TIA transient ischemic attack, PT-INR prothrombin time-international normalized
ratio, eGFR estimated glomerular filtration rate, NSAID non-steroidal
anti-inflammatory drug
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factors to the risk of bleeding. Finally, we cannot analyze
the relationship between PT-INR and thrombotic events
for warfarin in the present study. For such a purpose we
needed to collect cases developing thrombotic events and
matched controls.
Conclusion
The present study demonstrates that PT-INR 2.0 – 3.0
may be associated with a clinically permissible risk of
major bleeding while PT-INR ≥ 3.00 a significant risk in
elderly Japanese patients with NVAF. The present study
warrants further case-control studies with a greater num-
ber of patients to obtain conclusive evidence.
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